| Current Price | $96.87 | Mkt Cap | $3.2B |
|---|---|---|---|
| Open | $0.00 | P/E Ratio | 0.00 |
| Prev. Close | $96.87 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $0.00 - $0.00 | Volume | 21 |
| 52-Wk Range | $90.94 - $121.53 | Avg. Daily Vol. | 522,149 |
| Current Price | $96.87 | Mkt Cap | $3.2B |
|---|---|---|---|
| Open | $0.00 | P/E Ratio | 0.00 |
| Prev. Close | $96.87 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $0.00 - $0.00 | Volume | 21 |
| 52-Wk Range | $90.94 - $121.53 | Avg. Daily Vol. | 522,149 |
The best Bull and Bear pitches based on recency and number of recommendations.
https://www.fool.com/investing/2017/10/30/3-reasons-ive-been-aggressively-buying-intercept-p.aspx
I picked underperformed because the Intercept Molecule had some negative impact on cholesterol and it seems they didn't fix that problem yet. The FDA will probably want to look deeper into that. Furthermore another company that has a very good… More
Read the most recent pitches from players about ICPT.
Recs
odocoileus
(29.12)
Submitted: 1/30/2020 11:00:16 PM :
Start Price:
$124.46
NASDAQ:ICPT Score:
-62.58
I think the market has been a little harsh on ICPT. Ocaliva is likely to get approved for fibrosis and is likely to get used for less advanced NASH as well. It is further likely to have about a year of exclusivity. I think that GNFT, MDGL, VKTX and others will catch up, and will produce safer and more effective drugs. When that happens, I'm out of ICPT. For now I'm in. I expect it to get to $120 on approval and $200 the first year of sales. At that point I expect catalysts from other companies to start making investors nervous. Me included.
Recs
clangmead
(43.09)
Submitted: 7/18/2019 9:03:29 AM :
Start Price:
$68.84
NASDAQ:ICPT Score:
+24.34
NASH Fibrosis trials; NDA; MAA
Recs
Bigsef77
(67.36)
Submitted: 2/19/2019 10:07:10 AM :
Start Price:
$62.44
NASDAQ:ICPT Score:
+27.52
Intercept up 23% premarket on positive OCA data
Feb. 19, 2019 7:43 AM ET|About: Intercept Pharmaceuticals (ICPT)|By: Douglas W. House, SA News Editor
Intercept Pharmaceuticals (NASDAQ:ICPT) is up 23% premarket on light volume following its announcement of positive results from a Phase 3 clinical trial, REGENERATE, evaluating obeticholic acid (OCA) in patients with liver fibrosis (scarring) due to nonalcoholic steatohepatitis (NASH).
The study met one co-primary endpoint, a statistically significant proportion of patients achieving at least one stage improvement in fibrosis with no worsening of NASH at month 18 (p=0.0002), but failed to meet the other, the proportion of patients achieving NASH resolution with no worsening of liver fibrosis. The FDA agreed that only one endpoint needed to be met in order to be judged successful.
The data will be presented at the European Association for the Study of the Liver (EASL): International Liver Congress in Vienna April 10 - 14.
The company plans to file a U.S. marketing application in H2.
See all stocks on the move »
Find the members with the highest scoring picks in ICPT.
alkusari (< 20) Score: +443.87
The Score Leader is the player with the highest score across all their picks in ICPT.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| vzwatmrk | < 20 | 1/10/2014 |
|
5Y | $455.50 | -79.19% | +83.57% | +162.76 | 0 Comment | |
| Halffrenzy | 25.64 | 1/10/2014 |
|
5Y | $438.98 | -78.41% | +83.94% | +162.35 | 0 Comment | |
| jjc007007 | 62.67 | 2/5/2014 |
|
5Y | $296.00 | -67.98% | +91.97% | +159.95 | 0 Comment | |
| sinvestor | 71.65 | 1/14/2014 |
|
3M | $361.00 | -73.74% | +84.82% | +158.56 | 1 Comment | |
| kevrose31 | 79.66 | 1/10/2014 |
|
1Y | $373.00 | -74.59% | +83.14% | +157.73 | 0 Comment | |
| NewbiesRock | < 20 | 2/18/2014 |
|
5Y | $353.89 | -73.21% | +82.90% | +156.12 | 4 Comments | |
| kayakmastr | 74.06 | 1/13/2014 |
|
1Y | $339.87 | -72.11% | +83.38% | +155.49 | 0 Comment | |
| alexeysm | 45.00 | 1/13/2014 |
|
1Y | $339.87 | -72.11% | +83.38% | +155.49 | 0 Comment | |
| Figgie27 | < 20 | 1/13/2014 |
|
3M | $339.87 | -72.11% | +83.38% | +155.49 | 0 Comment | |
| gillet01 | < 20 | 4/7/2014 |
|
5Y | $298.86 | -68.28% | +82.22% | +150.50 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
